SG153831A1 - Use of renin inhibitors in therapy - Google Patents

Use of renin inhibitors in therapy

Info

Publication number
SG153831A1
SG153831A1 SG200904145-0A SG2009041450A SG153831A1 SG 153831 A1 SG153831 A1 SG 153831A1 SG 2009041450 A SG2009041450 A SG 2009041450A SG 153831 A1 SG153831 A1 SG 153831A1
Authority
SG
Singapore
Prior art keywords
hypertension
restenosis
syndrome
therapy
renoprotection
Prior art date
Application number
SG200904145-0A
Other languages
English (en)
Inventor
David Louis Feldman
Steven Zelenkofske
Michaela Dinboeck
Margaret Forney Prescott
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG153831A1 publication Critical patent/SG153831A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG200904145-0A 2004-03-17 2005-03-16 Use of renin inhibitors in therapy SG153831A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55387704P 2004-03-17 2004-03-17
US55735804P 2004-03-29 2004-03-29

Publications (1)

Publication Number Publication Date
SG153831A1 true SG153831A1 (en) 2009-07-29

Family

ID=34962409

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200904145-0A SG153831A1 (en) 2004-03-17 2005-03-16 Use of renin inhibitors in therapy

Country Status (15)

Country Link
US (1) US20080161321A1 (fr)
EP (2) EP1729749A2 (fr)
JP (2) JP2007529459A (fr)
KR (1) KR20070006774A (fr)
AU (2) AU2005224014B9 (fr)
BR (1) BRPI0508880A (fr)
CA (1) CA2558020A1 (fr)
IL (2) IL177831A0 (fr)
MA (1) MA28535B1 (fr)
NO (1) NO20064672L (fr)
NZ (2) NZ586285A (fr)
RU (2) RU2426532C2 (fr)
SG (1) SG153831A1 (fr)
TW (1) TW200605867A (fr)
WO (1) WO2005089731A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060416A1 (es) 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
ITMI20050150A1 (it) 2005-02-03 2006-08-04 Umberto Cornelli Prodotti alimentari
CN101291662A (zh) * 2005-10-21 2008-10-22 诺瓦提斯公司 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
BRPI0707518A2 (pt) * 2006-02-06 2011-05-10 Novartis Ag combinaÇço de compostos orgÂnicos
ITMI20060384A1 (it) * 2006-03-03 2007-09-04 Umberto Cornelli Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
WO2008074001A1 (fr) * 2006-12-15 2008-06-19 Novartis Ag Inhibiteurs de rénine pour la prévention et le traitement de l'hypertension chez les patients obèses
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
US20090054473A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
AR077428A1 (es) * 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
AU2010305901A1 (en) 2009-10-14 2012-05-24 Rainer Oberbauer Acute kidney injury risk testing
US10780143B2 (en) 2012-09-19 2020-09-22 University Of Utah Research Foundation Compositions and methods of use for (pro)renin receptor antagonists
US9586995B2 (en) 2012-09-19 2017-03-07 University Of Utah Research Foundation Compositions and methods of use for (pro)renin receptor
US9573976B2 (en) 2012-09-19 2017-02-21 University Of Utah Research Foundation Antagonist for (pro)renin receptor for the treatment of hypertension and diabetes
WO2016019226A1 (fr) * 2014-08-01 2016-02-04 University Of Utah Research Foundation Compositions et procédés d'utilisation d'antagonistes du récepteur de la (pro)rénine
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
WO2017011772A1 (fr) * 2015-07-16 2017-01-19 Abbvie, Inc. Traitement du syndrome néphrotique à résistance multimédicamenteuse (mdr-ns) chez les enfants
MA44836A (fr) 2015-08-26 2018-07-04 Univ Texas Procédés de traitement du syndrome polykystique des reins
WO2017159574A1 (fr) * 2016-03-18 2017-09-21 テルモ株式会社 Dispositif de mesure de fonction cardiaque, procédé de mesure de fonction cardiaque et programme de mesure de fonction cardiaque
KR20230174238A (ko) 2021-04-21 2023-12-27 니혼 메디피직스 가부시키가이샤 방사성 항종양제

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1962497C3 (de) 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
US3931305A (en) 1973-08-20 1976-01-06 Standard Oil Company Terephthalic acid recovery by continuous flash crystallization
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4885292A (en) * 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
CA1334092C (fr) 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
DK0403159T3 (da) 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
US5194605A (en) * 1989-12-08 1993-03-16 Merck & Co., Inc. Cyclic renin inhibitors containing 2-substituted (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid, 2-substituted (3S,4S)-5-cyclohexyl-3,4-di-hydroxy pentanoic acid or 2-substituted (4S,5S)-5-amino-6-cyclohexyl-4-hydroxyhexanoic acid or its analogs
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
ES2130170T3 (es) * 1990-12-14 1999-07-01 Smithkline Beecham Corp Composiciones bloqueantes del receptor de la angiotensina ii.
FI112942B3 (fi) 1991-02-21 2012-03-13 Daiichi Sankyo Co Ltd Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi
ZA921381B (en) * 1991-03-01 1992-11-25 Fujisawa Pharmaceutical Co New use of amino acid derivatives
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
TW226375B (fr) 1991-10-24 1994-07-11 American Home Prod
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
PL175392B1 (pl) 1993-04-27 1998-12-31 Smithkline Beecham Corp Pochodne indanu, kompozycja farmaceutyczna, zwłaszcza do antagonizowania receptorów endoteliny oraz sposób wytwarzania pochodnych indanu
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
CN1049219C (zh) 1993-08-18 2000-02-09 万有制药株式会社 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
JP3741441B2 (ja) 1994-08-19 2006-02-01 アボツト・ラボラトリーズ エンドセリン・アンタゴニスト
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (fr) 1994-12-20 1997-08-21 Hoffmann La Roche
WO1997009311A1 (fr) 1995-09-07 1997-03-13 F. Hoffmann-La Roche Ag Nouvelles 4-(oxyalcoxyphenyl)-3-oxy-piperidines utiles pour traiter l'insuffisance cardiaque et renale
JP3087968B2 (ja) 1995-12-20 2000-09-18 山之内製薬株式会社 アリールエテンスルホンアミド誘導体及びその医薬組成物
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
AU1319697A (en) 1996-01-23 1997-08-20 Shionogi & Co., Ltd. Process for producing oleanolic acid analogs by culturing hairy root
DE69733557T2 (de) 1996-04-04 2005-11-03 Banyu Pharmaceutical Co., Ltd. Endothelin-antagonisten zur behandlung von herzversagen
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
RU2276997C2 (ru) * 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CA2463758A1 (fr) * 2001-10-18 2003-05-01 Novartis Ag Composes organiques
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
KR20050008717A (ko) * 2002-05-17 2005-01-21 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는약제학적 조성물
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US20030229007A1 (en) * 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
EP1519920A1 (fr) * 2002-06-27 2005-04-06 Actelion Pharmaceuticals Ltd. Nouveaux derives de tetrahydropyridine en tant qu'inhibiteurs de renine
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
WO2004100871A2 (fr) * 2003-05-09 2004-11-25 Pharmacia Corporation Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine
CA2536975A1 (fr) * 2003-08-28 2005-03-17 Nitromed, Inc. Composes diuretiques nitroses et nitrosyles, compositions et procedes d'utilisation correspondants
AU2004295092A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
RU2006130005A (ru) * 2004-01-22 2008-02-27 Новартис АГ (CH) Комбинация органических соединений
WO2005077418A1 (fr) * 2004-02-17 2005-08-25 Novartis Ag Combinaison d'un inhibiteur de la renine et de diuretiques

Also Published As

Publication number Publication date
MA28535B1 (fr) 2007-04-03
RU2006136091A (ru) 2008-04-27
WO2005089731A2 (fr) 2005-09-29
AU2005224014B2 (en) 2009-07-16
CA2558020A1 (fr) 2005-09-29
EP1977741A3 (fr) 2009-10-14
JP2011178799A (ja) 2011-09-15
NZ586285A (en) 2011-12-22
JP2007529459A (ja) 2007-10-25
RU2426532C2 (ru) 2011-08-20
KR20070006774A (ko) 2007-01-11
IL177831A0 (en) 2006-12-31
IL209964A0 (en) 2011-02-28
AU2009222444A1 (en) 2009-10-15
EP1977741A2 (fr) 2008-10-08
BRPI0508880A (pt) 2007-09-04
AU2005224014B9 (en) 2009-08-27
RU2010149052A (ru) 2012-06-10
NO20064672L (no) 2006-12-14
NZ549535A (en) 2010-11-26
EP1729749A2 (fr) 2006-12-13
WO2005089731A3 (fr) 2006-05-11
AU2005224014A1 (en) 2005-09-29
US20080161321A1 (en) 2008-07-03
TW200605867A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
SG153831A1 (en) Use of renin inhibitors in therapy
Schiffrin et al. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension
CN111278442B (zh) 用于治疗进行性纤维化间质性肺病(pf-ild)的活性剂的新组合
GB0423653D0 (en) Pharmaceutical compounds
WO2006037031A3 (fr) Formulations et procedes destines au traitement de maladies inflammatoires
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
WO2004069201A3 (fr) Composes utiles pour enduire des stents pour la prevention et le traitement de la stenose et de la restenose
WO2004001059A3 (fr) Inhibiteurs heterocycliques de kinases
WO2007126964A3 (fr) Inhibiteurs de kinase
CA2358400A1 (fr) Procedes de traitement d'etats associes a l'accumulation d'un excedent de matrice extracellulaire
RU2008135692A (ru) Комбинация органический х-соединений
JP2023030022A5 (fr)
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
EP3057590B1 (fr) Traitement de la fibrose hépatique à l'aide d'un inhibiteur de la cbp/caténine
Takai et al. New approaches to blockade of the renin–angiotensin–aldosterone system: chymase as an important target to prevent organ damage
RS52944B (en) ROFLUMILAST FOR TREATMENT OF PULMONARY HYPERTENSION
TNSN06292A1 (en) Use of renin inhibitors in therapy
EP2016944A3 (fr) Inhibiteur de l'angiogénèse comprenant un dérivé de la rifampicine
AU2004212305A1 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
Yuri et al. Effects of pipemidic acid, phenazopyridine HCl and sodium diclofenac on pain perception following endoscopic urological surgery: double-blinded randomized-controlled trial
BRPI0514907A (pt) derivados do pirrol [3,2 -c] piridina e processos para a sua preparação
NZ535199A (en) Use of an inhibitor or antagonist against tissue factor
EP2908820A1 (fr) Traitement de la fibrose pulmonaire à l'aide d'un inhibiteur de la cbp/caténine
AU2003259261B2 (en) Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure